Targeting Aberrant Sialylation to Treat Cancer

Jennifer Munkley1, Emma Scott2

  • 1Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK. Jennifer.munkley@ncl.ac.uk.

Insights

Cancer cell surface glycans, particularly sialylated glycans, drive tumor progression and metastasis. Targeting these aberrant sialic acid structures offers promising new therapeutic strategies for cancer treatment.

Area of Science:

  • Biochemistry
  • Oncology
  • Glycobiology

Background:

  • Cell surface carbohydrates (glycans) are frequently altered in cancer, influencing tumor progression and metastasis.
  • Aberrant glycan expression is implicated in all hallmarks of cancer.
  • Understanding cancer glycobiology, especially sialic acid modifications, presents therapeutic opportunities.

Purpose of the Study:

  • To summarize alterations in sialic acid biology within cancer.
  • To discuss advancements in targeting sialic acid for cancer therapeutics.

Main Methods:

  • Review of current literature on cancer glycobiology and sialic acid.
  • Analysis of emerging technologies for sialic acid-targeted therapies.

Main Results:

  • Upregulation of cancer-associated sialylated glycans is a key change in tumors.
  • Abnormal sialylation contributes to tumor growth, metastasis, and immune evasion.
  • Glycan-based targeting strategies are under clinical investigation.

Conclusions:

  • Targeting sialic acid moieties holds significant therapeutic potential in oncology.
  • Advances in understanding and targeting cancer glycans are paving the way for novel treatments.